Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Apher Dial. 2014 Jun;18 Suppl 1:9-13. doi: 10.1111/1744-9987.12197.

Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.

Author information

  • 1Department of Nephrology, Sakura Memorial Hospital, Saitama, Japan.

Abstract

In this study, we investigated the clinical effects of long-term administration of the phosphorus (P) binder lanthanum carbonate (LC), which was launched in Japan in 2009. The subjects were 58 dialysis patients who began receiving LC, and we evaluated the clinical effects for up to 36 months after treatment initiation. The average serum P concentration remained low during the 36-month study period, with a significant reduction from 6.25 mg/dL at the start of the study to 4.94 mg/dL after 36 months (P < 0.001). A significant reduction was also observed in the average serum calcium concentration after 36 months (P < 0.05), but not in the serum intact parathyroid hormone concentration. Significant reductions were also observed in the average serum total protein, albumin and potassium concentrations (P < 0.05). The dosages of LC increased by approximately 1.9-fold after 36 months, in contrast, the dosages of concomitantly used sevelamer hydrochloride and Ca carbonate preparations decreased. These results indicate that LC could be used to treat hyperphosphatemia without causing hypercalcemia, and would be useful for long-term treatment with hemodialysis patients.

© 2014 The Authors. Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis.

KEYWORDS:

laboratory parameters; lanthanum carbonate; long-term effects; serum phosphorus concentrations

PMID:
24953760
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk